Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Overview
3. Targeting DNA methylation
4. Epigenetics in cancer
5. Hallmarks of cancer altered by methylation
6. Knudson's two-hit hypothesis
7. Secondary cancers from chemotherapy
8. DNA methylation, decitabine, and azacitidine
9. How DNA methyltransferase inhibitors work?
10. Muscle differentiation induced by 5-azacytidine
11. Maintenance of DNA methylation
12. Inhibition of methylation vs. cytotoxicity
13. Azacitidine vs. decitabine
14. Vidaza (azacitidine) and Dacogen (decitabine)
15. Hypomethylating agents and hydroxyurea
16. Hydroxyurea effect
17. Aphidicolin effect
18. Cytidine analogs
19. Clinical experience of azacitidine and decitabine
20. Induction of epigenetic changes by 5-azacytidine
21. Clinical results of low dose decitabine
22. Azacitidine survival study
23. Overall survival: azacitidine vs. CCR
24. DNMTi in solid tumors
25. Azacitidine in solid tumors
26. Identifying the target
27. How do you measure DNA methylation?
28. Surrogate for global DNA methylation
29. Decitabine treatment in CML patient
30. Decitabine: methylation and clinical response
31. Decitabine: methylation dose response
32. Phase 1 clinical study of azacitidine
33. Treatment schema
34. Results: LINE-1 DNA methylation changes
35. DNA repetitive elements serve as a surrogate
36. Summary of clinical translational data
37. Identifying specific gene targets
38. Targets of DNA methylation in cancer
39. Illumina analysis of APL, CML and GIST
40. CML and APL hypermethylated genes algorithms
41. ABL methylation is specific to CML patients
42. ID4 methylation and cancer progression
43. DNA methylation in CML
44. Genes involved in CML progression
45. Next generation epigenomic technology
46. Azacitidine treatment of MDS: methylation
47. The role of the Philadelphia chromosome
48. Next generation DNMTi
49. Degradation of 5-aza-nucleosides
50. What's next?
51. 5-aza-2'-deoxycytidine and S110
52. Incorporation of azacytosine into a oligonucleotide
53. Capecitabine (Xeloda)
54. Reactivation of GFP is dependent upon CES1
55. Summary
56. Acknowledgements

Topics Covered

• DNA Methylation as a target for disease therapy
• Azacitidine and Decitabine are "mechanistic" inhibitors of DNA methylation
• Clinical experience with DNA methylation inhibitors
• Translational science of biomarkers for DNA methylation inhibitor therapy
• Next generation drugs to inhibit DNA methylation

Links

Series:

• DNA Methylation

Categories:

• Cancer
• Cell Biology
• Genetics & Epigenetics

Therapeutic Areas:

• Oncology

Talk Citation

Publication History

• Published on July 1, 2010

Financial Disclosures

• Dr. Allen Yang has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.